title: [Simultaneous and metachronous pelvic bone metastases from renal cell carcinoma necessitating hemipelvectomy: report of two cases].
abstract: Two patients, one with and one without a history of nephrectomy for renal cell carcinoma, presented with lower abdominal pain. One of them, a 49-year-old man, had tumors in the right kidney and the right ischiadic bone. He underwent nephrectomy and pathologic findings showed renal cell carcinoma (tubular type, granular cell subtype, INF-gamma, G2). The other patient, a 33-year-old man with a previous history of left nephrectomy for renal cell carcinoma (tubular type, granular cell subtype, INF-alpha, G2), was found to have a large tumor in the pelvis, extending from the pubic and iliac bones to the hip joint. Both patients underwent embolization of the hypervascular mass using a vascular coil followed by hemipelvectomy under general anesthesia. The pathology reports confirmed bone metastases from renal cell carcinoma. Both patients survived surgery and their postoperative courses were uneventful without urinary or bowel incontinence. However, impaired potency was noted in the latter case. Immunotherapy with INF-alpha was resumed immediately after surgery.
authors.affiliation: Department of Urology, University of the Ryukyus, School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Mukouyama
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Hatano
authors.forename: Y
authors.initials: Y
authors.lastname: Koyama
authors.forename: K
authors.initials: K
authors.lastname: Sugaya
authors.forename: T
authors.initials: T
authors.lastname: Miyazato
authors.forename: H
authors.initials: H
authors.lastname: Shinzato
authors.forename: F
authors.initials: F
authors.lastname: Nashiro
authors.forename: K
authors.initials: K
authors.lastname: Yamakawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000601:surgery; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D006428:Hemipelvectomy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010384:Pelvic Bones / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha